Evidence map›Paper›PMID 37024466›Full record

ArticleCell death & disease2023

A novel tumour enhancer function of Insulin-like growth factor II mRNA-binding protein 3 in colorectal cancer.

Davide Di Fusco, Antonio Di Grazia, Giulia Di Maggio, Maria Teresa Segreto, Andrea Iannucci, Claudia Maresca, Alessandro De Stefano, Giuseppe Sica, Carmine Stolfi, Giovanni Monteleone and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. NRF2 as a ferroptosis gatekeeper in colorectal cancer: implications for therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Davide Di FuscoDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Antonio Di GraziaDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Giulia Di MaggioDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Maria Teresa SegretoDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Andrea IannucciDepartment of Biomedicine and Prevention, University of 'Tor Vergata', Rome, Italy.
Claudia MarescaDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Alessandro De StefanoDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.
Giuseppe SicaDepartment of Surgery, University of 'Tor Vergata', Rome, Italy.
Carmine StolfiDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.ORCID 0000-0002-6354-2443
Giovanni MonteleoneDepartment of Systems Medicine, University of 'Tor Vergata', Rome, Italy.ORCID 0000-0003-1339-9076
Ivan MonteleoneDepartment of Biomedicine and Prevention, University of 'Tor Vergata', Rome, Italy. ivan.monteleone@uniroma2.it.ORCID 0000-0002-3212-832X
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRC cells evolve a variety of strategies to limit or circumvent apoptosis cell death. RNA binding proteins (RBPs) regulate many of the molecular mechanisms that underlie the development of cancer. The insulin-like growth factor II mRNA-binding proteins (IMP) family are oncofoetal RBPs, consisting of IMP1, IMP2 and IMP3, which have an important role in RNA metabolism. IMP3 is highly expressed in colorectal cancer (CRC) tissue, where its expression often correlates with poor prognosis. However, the role of IMP3 in CRC is not fully understood. IMP3 expression was analysed using a public database and by Western blotting and immunohistochemistry in human colon samples derived from patients with sporadic CRC and healthy subjects. To address whether IMP3 controls cancer cell survival, we analysed cell death pathways in in vitro and in vivo experiments after IMP3 downregulation by siRNA or an antisense oligonucleotide. IMP3 was highly expressed in CRC samples compared to normal control tissues. The knockdown of IMP3 enhanced a caspase-independent cell death in CRC cell lines. Furthermore, the treatment of CRC cells with IMP3 siRNA did not alter the expression of GSDMD, GPX-4 and the activated form of RIP3, three key molecules that govern pyroptosis, ferroptosis and necroptosis, respectively. Abrogation of IMP3 in CRC significantly reduced Bcl-2 and Bcl-xL mRNA and was associated with an altered mitochondrial membrane potential that allowed the nuclear migration of the apoptosis-inducing factor (AIF). Moreover, specific immunoprecipitation experiments on CRC human cell lines indicated that IMP3 binds Bcl-2 and Bcl-xL mRNA, suggesting that IMP3 acts as a regulator of the intrinsic apoptotic pathway through the surveillance of anti-apoptotic Bcl mRNA metabolism. Finally, we showed that IMP3 block inhibited the growth of CRC cell lines in vivo after transplantation into immunodeficient mice. Altogether, these data support a novel role for IMP3 in controlling the intrinsic caspase-independent apoptotic pathway in CRC.

Indexed as

Colorectal NeoplasmsInsulin-Like Growth Factor IIAnimalsBiomarkers, TumorCaspasesHumansMiceProto-Oncogene Proteins c-bcl-2Ribonucleoproteins, Small NucleolarRNA, MessengerRNA, Small InterferingBiomarkers, TumorCaspasesIMP3 protein, humanInsulin-Like Growth Factor IIProto-Oncogene Proteins c-bcl-2Ribonucleoproteins, Small NucleolarRNA, MessengerRNA, Small Interfering

Identifiers

PMID37024466
PMCPMC10079693
OpenAlexW4362667168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.